A Randomized Open‐Label, Multi‐Center Pivotal Study of ANG1005 Compared With Physician's Best Choice in HER2‐Negative Breast Cancer Patients With Newly Diagnosed Leptomeningeal Carcinomatosis and Previously Treated Brain Metastases (ANGLeD). This evidence concerns the gene ERBB2 and breast carcinoma.